The DPP forms are released as papers are published. The following forms are currently available:

Screening Forms

Screening Step 2 Inventory – Eligibility Checklist (Form S01)
Inclusion and exclusion criteria for potential participants

Screening Step 2 Inventory (Form S03)
BMI, arm blood pressures, urinalysis, current medications, and pregnancy/diabetes information; OGTT qualification, progression and local results; demographics and complete blood count (CBC) results.

Screening Step 3 Inventory - Start (Form S05)
History on family, weight, smoking, aspirin use, cardiovascular and stroke/TIA, other diseases/symptoms, diet, and medical history for women; anthropometric and ankle/arm systolic blood pressure; dispensing of medication for run-in.

Screening Step 3 Inventory - End (Form S06)
Run-in compliance and adverse event assessment; personal and socioeconomic information

Screening Step 4 Inventory - Randomization (Form S07)
Adverse event assessment, pregnancy test result and current prescription medications; final eligibility review, micro-computer randomization and dispensing of coded medication.

Follow-up Forms (Post-Randomization)

Standard Follow-up Visit Inventory (Form F01)
Completed every 3 months (except for annual follow-up visits): adverse event assessment, pregnancy questions, and current concomitant prescription medications; for the pharmacological treatment participants, coded medication compliance and dispensing, and at the end-month 6 visit only, CBC results. At mid-year follow-up visits (end-months 6, 18, ...): weight and arm blood pressures.

Major Follow-up Visit Inventory (Form F02)
Completed during annual follow-up visits (end-year 1, end-year 2, ...), end of study and at the time of the primary outcome (confirmed development of diabetes): weight, waist circumference, hip girth, and arm blood pressures; adverse event assessment, pregnancy questions and current concomitant prescription medications; for the pharmacological treatment participants, coded medication compliance and dispensing, and CBC results. At end-year 1 and end of study: skin-fold thickness and sagittal diameter. At end-year 3: ankle/arm systolic blood pressure.

Interim Follow-up Visit Inventory (Form F03)

Completed at titration visits for coded metformin and follow-up visits when the Standard Follow-up Visit Inventory (Form F01) and Major Follow-up Visit Inventory (Form F02) are not completed. Form F03 records the following: adverse events, pregnancy questions, coded medication and arm blood pressure for hypertension management.

Missed Follow-up Visit Report (Form F04)

Completed anytime a participant misses either a standard or major scheduled follow-up visit. Form F04 records the date and reason for the missed visit.

Medication Adherence Interview (Form F05)

Completed when medication adherence is assessed on the Standard (Form F01) or Major (Form F02) Follow-up Visit Inventory. This form is also completed at the Month 1 Titration Visit with the Interim (Form F03) Follow-up Visit Inventory. Complete this form only if the participant has taken any coded metformin since the last visit. The Medication Adherence Interview is for all DPP participants taking coded metformin, regardless of level of adherence. Complete the interview and F05 form, and then transfer appropriate data to Section H (Coded Medication) of the corresponding Follow-up Visit Inventory.

Medication Adherence Interview Code (Form F05 Code)

Home Visit Inventory (Form F06)

Completed for inactive participants off their coded medication for any Mid-Year or Annual visit conducted outside the DPP clinic.

Lifestyle Intervention Group Forms

Lifestyle Contact - In Person (Form L03)

Completed for all in-person contacts: Includes nature of session (type and duration), self-monitoring information, and physical activity and weight status.

Lifestyle Physical Activity Log (Form L04)

Completed for each supervised physical activity session. If more than 15 participants attend a session please attach an additional form.

Lifestyle Group Session Log (Form L05)

Completed for each group session. If more than 15 participants attend a session please attach an additional form.

Screening and Follow-UP Questionnaires

Available to approved requests only

Event data forms (As Needed)

Adverse Event Report (Form E01)
Serious Adverse Event Report (Form E02)
Pregnancy Confirmation Report (Form E04)
Pregnancy Outcome Report (Form E05)
Mortality Event Report (Form E06)

Risk Status Report

CHD Risk Status Report (Form R04)

Completed whenever samples are collected for CBL determination of lipid profile. Form R04 records the non-lipid coronary heart disease (CHD) risk factors based on 1993 NCEP guidelines in adults.

Troglitazone Forms

Participants Randomized to Troglitazone Follow-Up Visit Inventory (Form TR01)

Completed at all mid-year and annual follow-up visits for participants randomized to troglitazone. (End-month 6, 12, 18, ...) Form TR1 records the following: weight, blood pressure, adverse events and concomitant medications.

Participants Randomized to Troglitazone Group Session Log (Form TR02)

Completed for each troglitazone group session. If more than 15 participants attend a session please attach an additional form.

All Currently Available Forms